How venture capitalists decide which new medical technologies come to exist
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
To encourage the commercial translation of biomedical discoveries, public policies increasingly seek to stimulate the venture capital industry. Very little is known, however, about the way venture capitalists assess the likely benefits new technologies may bring to clinical practice and healthcare systems. Drawing on a five-year fieldwork conducted in Quebec (Canada), which included in-depth interviews and document analysis, we explore why capital investors choose to invest in certain health technology-based ventures and how they influence the innovation process. Our findings clarify how capital investors: first, use market-oriented valuations when they pick and ‘coach’ technology entrepreneurs; second, act to transform and protect their investments; and finally, exert their authority along the technology development process. Current innovation policies should be carefully examined because capital investors’ understanding of the world in which they operate largely determines which health technologies make their way into healthcare systems and which may never come into existence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lehoux et al distinguish between a health technology’s upstream value as viewed by investors (especially the business case for generating profits, further spin-offs, and highly qualified jobs), drug and device regulators (preliminary evidence of efficacy and safety), and financial regulators (auditable business processes and governance), and its downstream value as viewed by clinicians and policy”
Citations
Cites
Research Design: Qualitative, Quantitative, and Mixed Methods Approaches
Creswell, J. W. (1994) · Cited by 35,473
Baum, J. A. C., & Silverman, B. S. (2004) · Journal of Business Venturing · doi:10.1016/s0883-9026(03)00038-7 · Cited by 1,418
Approaching adulthood: the maturing of institutional theory
Scott, W. R. (2008) · Theory and Society · doi:10.1007/s11186-008-9067-z · Cited by 1,311
The Nonspread of Innovations: the Mediating Role of Professionals
Ferlie, E., Fitzgerald, L., Wood, M., & Hawkins, C. (2005) · Academy of Management Journal · doi:10.5465/amj.2005.15993150 · Cited by 1,106
Critical junctures in the development of university high-tech spinout companies
Vohora, A., Wright, M., & Lockett, A. (2004) · Research Policy · doi:10.1016/s0048-7333(03)00107-0 · Cited by 1,057
30 years after Bayh–Dole: Reassessing academic entrepreneurship
Grimaldi, R., Kenney, M., Siegel, D. S., & Wright, M. (2011) · Research Policy · doi:10.1016/j.respol.2011.04.005 · Cited by 913
The Blended Value Proposition: Integrating Social and Financial Returns
Emerson, J. (2003) · California Management Review · doi:10.2307/41166187 · Cited by 776
Why do venture capital firms exist? theory and canadian evidence
Amit, R., Brander, J., & Zott, C. (1998) · Journal of Business Venturing · doi:10.1016/s0883-9026(97)00061-x · Cited by 746
Leonardi, P. M., & Barley, S. R. (2010) · Academy of Management Annals · doi:10.5465/19416521003654160 · Cited by 733 · cited 4×
“‘left censor’ technology construction processes (Leonardi and Barley 2010), which reduces our ability to call into question the macro-social dynamics that affect which new technologies come to exist (Lazonick and Tulum 2011).”
BackgroundInfluentialThe ‘‘what’’and ‘‘how’’of case study rigor: three strategies based on published work
Gibbert, M., & Ruigrok, W. (2010) · Organizational Research Methods · doi:10.1177/1094428109351319 · Cited by 506
Success Factors in New Ventures: A Meta‐analysis*
Song, M., Podoynitsyna, K., Van Der Bij, H., & Halman, J. I. M. (2008) · Journal of Product Innovation Management · doi:10.1111/j.1540-5885.2007.00280.x · Cited by 483
Bertoni, F., Colombo, M. G., & Grilli, L. (2011) · Research Policy · doi:10.1016/j.respol.2011.03.008 · Cited by 443
Public R&D and social challenges: What lessons from mission R&D programs?
Foray, D., Mowery, D. C., & Nelson, R. R. (2012) · Research Policy · doi:10.1016/j.respol.2012.07.011 · Cited by 441
Kamps, H. J. (2020) · Pitch Perfect · doi:10.1007/978-1-4842-6065-4_2 · Cited by 388
Zider, B. (1998) · PubMed · Cited by 298
Lazonick, W., & Mazzucato, M. (2013) · Industrial and Corporate Change · doi:10.1093/icc/dtt019 · Cited by 284 · cited 3×
“We thus concur with Lazonick and Mazzucato (2013) who underscored the fact that innovation policies reward value extraction over value creation activities.”
BackgroundResultInstitutions and venture capital
Lerner, J., & Tå̊g, J. (2013) · Industrial and Corporate Change · doi:10.1093/icc/dts050 · Cited by 213
US Biopharmaceutical Finance and the Sustainability of the Biotech Business Model
Lazonick, W., & Tulum, O. (2011) · SSRN Electronic Journal · doi:10.2139/ssrn.2257932 · Cited by 199
Sabatier, V., Craig-Kennard, A., & Mangematin, V. (2012) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2011.12.007 · Cited by 187
Lehoux, P., Daudelin, G., Williams–Jones, B., Denis, J., & Longo, C. J. (2014) · Research Policy · doi:10.1016/j.respol.2014.02.001 · Cited by 183
Self-citationPhysician-Industry Cooperation In The Medical Device Industry
Chatterji, A., Fabrizio, K. R., Mitchell, W., & Schulman, K. A. (2008) · Health Affairs · doi:10.1377/hlthaff.27.6.1532 · Cited by 170
The value added by government venture capital funds compared with independent venture capital funds
Luukkonen, T., Deschryvere, M. K. S., & Bertoni, F. (2013) · Technovation · doi:10.1016/j.technovation.2012.11.007 · Cited by 170
Oakey, R. (2003) · Venture Capital · doi:10.1080/1369106032000097049 · Cited by 86
Lehoux, P., Williams-Jones, B., Miller, F., Urbach, D., & Tailliez, S. (2008) · Journal of Health Services Research & Policy · doi:10.1258/jhsrp.2008.007173 · Cited by 71
Self-citationFleming, J. J. (2015) · Health Affairs · doi:10.1377/hlthaff.2014.1051 · Cited by 50
Financial Market and Technological Innovation
Hirsch‐Kreinsen, H. (2011) · Industry and Innovation · doi:10.1080/13662716.2011.573954 · Cited by 46
Redirecting Innovation in U.S. Health Care: Options to Decrease Spending and Increase Value
Garber, S., Gates, S. M., Keeler, E. B., Vaiana, M. E., Mulcahy, A. W., Lau, C., & Kellermann, A. L. (2014) · Rand health quarterly · doi:10.7249/rhq-04-01-03 · Cited by 42
Fueling Innovation In Medical Devices (And Beyond): Venture Capital In Health Care
Ackerly, D. C., Vidal, A. V., Diener, L. W., Dossary, K. L., & Schulman, K. A. (2008) · Health Affairs · doi:10.1377/hlthaff.28.1.w68 · Cited by 36
Venture capital: now and after the dotcom crash
Pierrakis, Y. (2010) · Research Repository (Kingston University London) · Cited by 25
Biomedical Innovation In The Era Of Health Care Spending Constraints
Robinson, J. C. (2015) · Health Affairs · doi:10.1377/hlthaff.2014.0975 · Cited by 25
Lehoux, P., Daudelin, G., Hivon, M., Miller, F. A., & Denis, J. (2014) · Sociology of Health & Illness · doi:10.1111/1467-9566.12097 · Cited by 23
Self-citationSampat, B. N., & Drummond, M. (2011) · Journal of Health Politics Policy and Law · doi:10.1215/03616878-1191126 · Cited by 18
Lehoux, P., Miller, F. A., Hivon, M., Demers‐Payette, O., & Urbach, D. R. (2013) · Health Policy and Technology · doi:10.1016/j.hlpt.2013.05.003 · Cited by 16
Self-citationStyhre, A. (2014) · Technology Analysis and Strategic Management · doi:10.1080/09537325.2014.900170 · Cited by 14
Catalyzing capital for Canada's life sciences industry
Tucker, J. E., Chakma, J., Fedak, P. W. M., & Cimini, M. (1969) · Journal of Commercial Biotechnology · doi:10.1057/jcb.2011.26 · Cited by 7
Endovascular Repair of Aortic Disease: A Venture Capital Perspective
Buchanan, L., Stavropoulos, S. W., Resnick, J. B., & Solomon, J. (2009) · Seminars in Interventional Radiology · doi:10.1055/s-0029-1208384 · Cited by 6
Research works printed but not linked: 2
- Flyvbjerg B. (2011) ‘Case study’ in The Sage Handbook of Qualitative Research, 4th edition, Denzin N. K. Lincoln Y. S. (eds), pp. 301–16. Thousand Oaks, CA: Sage.
- 10.1016/j.respol.2011.05.021 · doi:10.1016/j.respol.2011.05.021 · Paper page
Cited by
Greenhalgh, T., Wherton, J., Papoutsi, C., Lynch, J., Hughes, G., A'Court, C., Hinder, S., Fahy, N., Procter, R., & Shaw, S. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.8775 · Cited by 2,887
“Lehoux et al distinguish between a health technology’s upstream value as viewed by investors (especially the business case for generating profits, further spin-offs, and highly qualified jobs), drug and device regulators (preliminary evidence of efficacy and safety), and financial regulators (auditable business proces…”
Greenhalgh, T., Wherton, J., Papoutsi, C., Lynch, J., Hughes, G., A’Court, C., Hinder, S., Procter, R., & Shaw, S. (2018) · BMC Medicine · doi:10.1186/s12916-018-1050-6 · Cited by 232
Lehoux, P., Roncarolo, F., Silva, H. P., Boivin, A., Denis, J.-L., & Hébert, R. (2018) · International Journal of Health Policy and Management · doi:10.15171/ijhpm.2018.110 · Cited by 88
Self-citationThe Unexplored Contribution of Responsible Innovation in Health to Sustainable Development Goals
Lehoux, P., da Silva, H. P., Sabio, R. P., & Roncarolo, F. (2018) · Sustainability · doi:10.3390/su10114015 · Cited by 99
Self-citationLehoux, P., Miller, F. A., Daudelin, G., & Denis, J.-L. (2017) · International Journal of Health Policy and Management · doi:10.15171/ijhpm.2017.11 · Cited by 74
Self-citation
Metadata
- Authors
- Lehoux, P., Miller, F. A., Daudelin, G., & Urbach, D. R.
- Affiliations
- Université de Montréal (CA)
- University of Toronto (CA)
- Corresponding author
- Lehoux, P.
- Venue
- Science and Public Policy
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08-27
- Volume
- 43
- Issue
- 3
- Pages
- 375-385
- ISSN
- 0302-3427 (ISSN-L)
- 1471-5430
- OpenAlex
- W2337437189
- Cited by
- 35
- References
- 37
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 5 · 2023: 5 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 6 · 2016: 2
- FWCI
- 19.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science and Public Policy (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- European Commission
- Topics
- Social Sciences › Economics, Econometrics and Finance › Finance › Private Equity and Venture Capital
- Social Sciences › Business, Management and Accounting › Management of Technology and Innovation › Biotechnology and Related Fields
- Social Sciences › Economics, Econometrics and Finance › Finance › Community Development and Social Impact
- Keywords
- venture capital, health technology innovation, technology entrepreneurs, investment valuation, innovation policy, technology development process, health technology adoption
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.